Skip to main content

Table 2 Clinical and bacteriological outcomes, mortality, and adverse events in both treatment groups after matching

From: Low-dose intravenous plus inhaled versus intravenous polymyxin B for the treatment of extensive drug-resistant Gram-negative ventilator-associated pneumonia in the critical illnesses: a multi-center matched case–control study

  IH + IV polymyxin B (n = 44) IV polymyxin B (n = 88) p value
Outcomes
 Clinical outcomes
  Clinical cure 19(43.2) 24(27.3) 0.066
  Clinical improvement 15(34.1) 27(30.7) 0.692
  Clinical failure 10(22.7) 35(39.8) 0.051
  Recurrence 0(0.0) 2(2.3) 0.552
  Favorable clinical outcome 34(77.3) 51(58.0) 0.029
  Unfavorable clinical outcome 10(22.7) 37(42.0)  
Bacteriological outcomes
 Eradication 16(36.4) 21(23.9) 0.132
 Persistence 18(40.9) 45(51.1) 0.267
 Colonization 1(2.3) 12(13.6) 0.079
 Recurrence 9(20.5) 10(11.4) 0.161
In-hospital mortality
 All-cause 15(34.1) 37(42.0) 0.378
 VAP-related 12(27.3) 30(34.1) 0.428
 28-day mortality 7(15.9) 22(25.0) 0.234
Side effects
 AKI 3(6.8) 5(5.7)  > 0.999
 Bronchospasm 4(9.1) 0
 Darkening of skin 44(100) 88(100)
 Facial flushing 14(31.8) 25(28.4) 0.840